Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901
Authors:
- Shin SaitoSSShin Saito
- Yosuke KawashimaYKYosuke Kawashima
- Hisashi TanakaHTHisashi Tanaka
- Naruo YoshimuraNYNaruo Yoshimura
- Yoko TsukitaYTYoko Tsukita
- Ryota SaitoRSRyota Saito
- Taku NakagawaTNTaku Nakagawa
- Minehiko InomataMIMinehiko Inomata
- Hiromi NagashimaHNHiromi Nagashima
- Shunichi SugawaraSSShunichi Sugawara
Open Access
Abstract
The emergence of immune checkpoint inhibitors (ICIs) has revolutionized standard therapies for non-small cell lung cancer (NSCLC)Keywords
This publication has 31 references indexed in Scilit:
- Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-AnalysisJTO Clinical and Research Reports, 2022
- Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort studyJournal of Cancer Research and Clinical Oncology, 2022
- Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysisInternational Immunopharmacology, 2021
- Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer PatientsClinical Lung Cancer, 2020
- Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancerCancer Chemotherapy and Pharmacology, 2019
- Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative for EGFR mutation and ALK fusionLung Cancer, 2019
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialThe Lancet, 2014
- Japanese experience with second-line chemotherapy with low-dose (60 mg/m2) docetaxel in patients with advanced non-small-cell lung cancerCancer Chemotherapy and Pharmacology, 2001